Liver Cirrhosis Research Today is a free monthly online journal that collates and summarizes the latest research about Liver Cirrhosis, including details on alcohol, treatment, drugs, effects, causes.

Volume 4 (2007), Issue 3 (March)

1. Primary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sjögren's syndrome and thyroid dysfunction.
   Clin Rheumatol, 26(4): 596-600. [Abstract] [Full-text]
2. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.
   Hepatology, 45(3): 579-87. [Abstract] [Full-text]
3. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis.
   Hepatology, 45(3): 659-65. [Abstract] [Full-text]
4. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis.
   Hepatology, 45(3): 569-78. [Abstract] [Full-text]
5. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.
   Hepatology, 45(3): 549-59. [Abstract] [Full-text]
6. Isoleucine infusion during "simulated" upper gastrointestinal bleeding improves liver and muscle protein synthesis in cirrhotic patients.
   Hepatology, 45(3): 560-8. [Abstract] [Full-text]
7. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.
   Hepatology, 45(3): 725-34. [Abstract] [Full-text]
8. Identification of hepatocytic and bile ductular cell lineages and candidate stem cells in bipolar ductular reactions in cirrhotic human liver.
   Hepatology, 45(3): 716-24. [Abstract] [Full-text]
9. Efficient hepatitis C antigen immunohistological staining in sections of normal, cirrhotic and tumoral liver using a new monoclonal antibody directed against serum-derived HCV E2 glycoproteins.
   Cancer Lett, 248(1): 81-8. [Abstract] [Full-text]
10. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy.
    Gut, 56(3): 390-5. [Abstract] [Full-text]
11. Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis.
    Gut, 56(3): 396-404. [Abstract] [Full-text]
12. Biliary tract cancer and stones in relation to chronic liver conditions: A population-based study in Shanghai, China.
    Int J Cancer, 120(9): 1981-5. [Abstract] [Full-text]
13. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients.
    Am J Med, 120(3): 280.e9-14. [Abstract] [Full-text]
14. A useful model to audit liver resolution from cirrhosis in rats using functional proteomics.
    J Surg Res, 138(2): 214-23. [Abstract] [Full-text]
15. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker.
    J Acquir Immune Defic Syndr, 44(4): 463-9. [Abstract] [Full-text]
16. Prevention of liver cirrhosis in rats by curcumin.
    Liver Int, 27(3): 373-83. [Abstract] [Full-text]
17. Progression to cirrhosis in hepatitis C patients: an age-dependent process.
    Liver Int, 27(3): 335-9. [Abstract] [Full-text]
18. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
    Clin Oncol (R Coll Radiol), 19(3): 197-203. [Abstract] [Full-text]
19. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C.
    J Hepatol, 46(4): 620-7. [Abstract] [Full-text]
20. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study.
    J Hepatol, 46(4): 613-9. [Abstract] [Full-text]
21. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients.
    J Hepatol, 46(4): 628-34. [Abstract] [Full-text]
22. Carbon monoxide-mediated activation of large-conductance calcium-activated potassium channels contributes to mesenteric vasodilatation in cirrhotic rats.
    J Pharmacol Exp Ther, 321(1): 187-94. [Abstract] [Full-text]
23. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7).
    J Hepatol, 46(4): 674-81. [Abstract] [Full-text]
24. Activation of the IGF1 system characterizes cholangiocyte survival during progression of primary biliary cirrhosis.
    J Histochem Cytochem, 55(4): 327-34. [Abstract] [Full-text]
25. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C.
    J Hepatol, 46(4): 587-95. [Abstract] [Full-text]
26. Effect of alpha-interferon and alpha-tocopherol in reversing hepatic cirrhosis in rats.
    Anat Histol Embryol, 36(2): 88-93. [Abstract] [Full-text]
27. Fat-containing nodules in the cirrhotic liver: chemical shift MRI features and clinical implications.
    AJR Am J Roentgenol, 188(4): 1009-16. [Abstract] [Full-text]
28. Inchin-ko-to prevents medium-term liver fibrosis in postoperative biliary atresia patients.
    Pediatr Surg Int, 23(4): 343-7. [Abstract] [Full-text]
29. Primary biliary cirrhosis: what we know and what we want to know about human PBC and spontaneous PBC mouse models.
    J Gastroenterol, 42(3): 189-95. [Abstract] [Full-text]
30. Portal diameter in the diagnosis of esophageal varices in 266 cirrhotic patients: which role?
    Ultrasound Med Biol, 33(4): 506-11. [Abstract] [Full-text]

© 2004-2008 Liver Cirrhosis Research Today. All Rights Reserved.